Hyamira Soft dermal filler belongs to the Hyamira range, produced by Apharm laboratory. This new line features sterile hyaluronic acid gels with varying viscosity and elasticity, designed to provide longer-lasting results compared to conventional injectable dermal fillers. A new generation of fillers ideal for subcutaneous applications. Hyamira Soft is a sterile, highly tolerated, viscoelastic filler made with cross-linked hyaluronic acid that is designed to last longer.
Hyamira increases the volume of the dermo-epidermal tissue due to its natural ability. Hyamira Soft and its sister product, Hyamira Basic, have both been designed to treat brow, tear trough, temples, and other finer lines and wrinkles. This allows the integration of the intercellular matrix while filling intradermal spaces and making the tissues firmer. The cross-linked hyaluronic acid contained in the product makes this filling effect longer-lasting and more stable. The skin slowly absorbs Hyamira Soft in 6 to 8 months, looking more natural for longer.
Hyamira is an innovative range of dermal fillers that are specifically designed for subcutaneous applications. These fillers are made with cross-linked hyaluronic acid, ensuring sterility and high tolerance. One of the key advantages of Hyamira is its ability to increase the volume of dermo-epidermal tissue. This is achieved through the hydrophilic nature of hyaluronic acid, which attracts water molecules and bonds with them. As a result, the intercellular matrix is integrated, intradermal spaces are filled, and the tissues become firmer. The cross-linking of hyaluronic acid in Hyamira ensures a longer-lasting and more stable filling effect. Over a period of 6 to 8 months, the skin gradually absorbs Hyamira, providing a natural and long-lasting result.
Composition
15 mg/ml Hyaluronic Acid without Lidocaine
Recommended Indications
Perioral lines
Smokers lines
Glabella
Tear Troughs
Brow
Temples
Needles = 2 x 30G * 1/2″
Storage = 2-25°C
Duration = 3-4 months
BDDE = <50 ppb
Reviews
There are no reviews yet.